Skip to main content

Table 1 Clinical status of RAp and HD

From: Interleukin-17A- or tumor necrosis factor α-mediated increase in proliferation of T cells cocultured with synovium-derived mesenchymal stem cells in rheumatoid arthritis

  RAp HD
Number of Patients 22 8
Sex   
  Men 11 (50%) 4 (50%)
  Woman 11 (50%) 4 (50%)
Age (years) 42 (38 to 56) 40 (35 to 46)
Disease duration (years) 3.1 (0.2 to 5.5) 2.6 (0.1 to 4.6)
Treatment, patients (%)   
  None 15 (68%) 7 (87.5%)
  MTX 2 (9%) -
  MTX + SSZ 2 (9%) -
  NSAIDs - 1 (12.5%)
  Otherb 3 (14%) -
VAS 14 (5 to 35) 1 (0 to 2)
  1. bOther treatments may have included corticosteroids, azathioprine, or leflunomide. In the HD group, disease duration refers to the duration of meniscus injury.
  2. HD, healthy donor; MTX, methotrexate; Rap, patients with rheumatoid arthritis (RA); SSZ, sulfasalazine; NSAIDs, nonsteroidal antiinflammatory drugs; VAS, visual analogue score.